Advertisement
Screener

Amylyx Pharmaceuticals, Inc. (AMLX) Graph

AMLX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue (m); Research and development $23.77M; Selling, general and administrative $21.93M.
  • 2026-03-31: Revenue (m); Cost of revenue (m); Research and development $27.61M; Selling, general and administrative $16.17M.
  • 2025-12-31: Revenue $0.00*; Cost of revenue $0.00*; Research and development $21.21M*; Selling, general and administrative $15.39M*.
  • 2025-09-30: Revenue $0.00; Cost of revenue $0.00; Research and development $19.86M; Selling, general and administrative $16.17M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)$23.77M$21.93M(m)(m)-$43.42M
2026-03-31(m)(m)$27.61M$16.17M(m)(m)-$41.28M
2025-12-31$0.00*$0.00*$21.21M*$15.39M*(m)$46.00K*-$33.00M*
2025-09-30$0.00$0.00$19.86M$16.17M(m)$0.00-$34.39M
2025-06-30$0.00$0.00$27.22M$15.64M(m)$0.00-$41.44M
2025-03-31$0.00$0.00$22.12M$15.68M(m)$0.00-$35.91M
2024-09-30$416.00K$0.00$21.24M$17.83M(m)$0.00-$72.70M
2024-06-30-$1.02M$8.00K$23.35M$21.65M(m)$0.00-$72.70M
2024-03-31$88.64M$5.95M$36.61M$57.76M(m)$242.00K-$118.79M
2023-09-30$102.69M$5.22M$30.04M$48.72M(m)$1.52M$20.89M
2023-06-30$98.22M$5.58M$29.04M$43.39M(m)$1.93M$22.07M
2023-03-31$71.43M$5.28M$24.19M$44.01M(m)-$170.00K$1.57M
2022-09-30$345.00K$172.00K$24.91M$29.94M(m)-$125.00K-$53.76M
2022-06-30(m)(m)$24.26M$29.99M$54.25M$174.00K-$54.07M
2022-03-31(m)(m)$21.46M$26.35M$47.81M$146.00K-$47.85M
2021-09-30$285.00K(m)$12.85M$10.35M(m)(m)-$23.14M
2021-06-30(m)(m)$10.93M(m)$18.59M(m)-$21.92M
2021-03-31(m)(m)$6.86M(m)$12.87M(m)-$14.52M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)$51.38M$38.09M(m)(m)-$84.71M
2025-06-30$0.00$0.00$49.34M$31.32M(m)$0.00-$77.35M
2024-06-30$87.62M$5.95M$59.95M$79.41M(m)$242.00K-$191.49M
2023-06-30$169.64M$10.86M$53.24M$87.40M(m)$1.76M$23.65M
2022-06-30(m)(m)$45.72M$56.34M$102.07M$320.00K-$101.92M
2021-06-30(m)(m)$17.79M(m)$31.45M(m)-$36.45M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$0.00$0.00$69.19M$47.49M$0.00-$111.74M
2024-09-30$88.04M$5.95M$81.19M$97.23M$242.00K-$264.20M
2023-09-30$272.34M$16.08M$83.27M$136.12M$3.28M$44.54M
2022-09-30$345.00K$172.00K$70.64M$86.28M$195.00K-$155.67M
2021-09-30$285.00K(m)$30.65M$24.01M(m)-$59.59M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$0.00$0.00$90.40M$62.89M$46.00K-$144.74M
2024-12-31$87.37M$5.95M$104.08M$114.33M-$393.00K-$301.74M
2023-12-31$380.79M$25.44M$128.19M$188.36M$5.03M$49.27M
2022-12-31$22.23M$2.99M$93.45M$127.13M$774.00K-$198.38M
2021-12-31$285.00K(m)$44.04M$38.93M(m)-$87.93M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
PRECIGEN, INC. (PGEN)United States$2.757B-12.94